Wednesday, 25 January 2012

MS pill Gilenya undergoing safety review

Source the MS Society:
The European Medicines Agency has begun a review of the 'benefits and risks' of the new MS pill Gilenya (aka fingolimod) following concerns over the treatment's effects on the heart after the first dose.   For more click here.